AUM Biosciences Doses First Patient in Phase 2 Clinical Trial of AUM001 in Metastatic Colorectal Cancer - Marketscreener.com

1 min to read

AUM Biosciences Doses First Patient in Phase 2 Clinical Trial of AUM001 in Metastatic Colorectal Cancer – Marketscreener.com

Ribbon Acquisition Corp Prices $50 Million Initial Public Offering

New York, New York, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Ribbon Acquisition Corp, a blank check company incorporated in the...
Ribbon Acquisition Corp Announces Closing of $50 Million Initial Public Offering.

New York, New York, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ribbon Acquisition Corp (NASDAQ: RIBBU, the “Company”) today announced the...
D. Boral Capital Served as the Sole Underwriter on the IPO of BurTech Acquisition Corp (Nasdaq: BRKH) which Recently Completed an ~$894 Million Business Combination with Blaize, Inc. (“Blaize”)

WASHINGTON and EL DORADO HILLS, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- BurTech Acquisition Corp. (“BurTech”) (NASDAQ: BRKH), a publicly...
ISS, Glass Lewis and BlackRock Issue 2025 Voting Guidelines

As companies begin preparing for the 2025 proxy season, Institutional Shareholder Services Inc. (ISS) and Glass Lewis, the leading providers...
Yes, SPACs Do Dilute Investors: A Brief Response to Gulliver and Scott – Stanford Law School

Yes, SPACs Do Dilute Investors: A Brief Response to Gulliver and Scott Stanford Law School Source: Yes, SPACs Do Dilute Investors:...